These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 35863299)

  • 1. Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    Kasheke GDS; Holman SP; Robertson GS
    J Neuroimmunol; 2022 Sep; 370():577926. PubMed ID: 35863299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinematic gait parameters are highly sensitive measures of motor deficits and spinal cord injury in mice subjected to experimental autoimmune encephalomyelitis.
    Fiander MD; Stifani N; Nichols M; Akay T; Robertson GS
    Behav Brain Res; 2017 Jan; 317():95-108. PubMed ID: 27639322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis.
    Bonfiglio T; Olivero G; Merega E; Di Prisco S; Padolecchia C; Grilli M; Milanese M; Di Cesare Mannelli L; Ghelardini C; Bonanno G; Marchi M; Pittaluga A
    PLoS One; 2017; 12(1):e0170825. PubMed ID: 28125677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis.
    de Bruin NM; Schmitz K; Schiffmann S; Tafferner N; Schmidt M; Jordan H; Häußler A; Tegeder I; Geisslinger G; Parnham MJ
    Behav Brain Res; 2016 Mar; 300():160-74. PubMed ID: 26692368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    Koda T; Namba A; Nakatsuji Y; Niino M; Miyazaki Y; Sugimoto T; Kinoshita M; Takata K; Yamashita K; Shimizu M; Fukazawa T; Kumanogoh A; Mochizuki H; Okuno T
    PLoS One; 2018; 13(3):e0193986. PubMed ID: 29518148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis.
    Zhang J; Zhang ZG; Li Y; Ding X; Shang X; Lu M; Elias SB; Chopp M
    Neurobiol Dis; 2015 Apr; 76():57-66. PubMed ID: 25680941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.
    Wang X; Brieland JK; Kim JH; Chen YJ; O'Neal J; O'Neil SP; Tu TW; Trinkaus K; Song SK
    NMR Biomed; 2013 Dec; 26(12):1742-50. PubMed ID: 23939596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sagittal Plane Kinematic Gait Analysis in C57BL/6 Mice Subjected to MOG35-55 Induced Experimental Autoimmune Encephalomyelitis.
    Fiander MD; Chedrawe MA; Lamport AC; Akay T; Robertson GS
    J Vis Exp; 2017 Nov; (129):. PubMed ID: 29155752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice.
    Chedrawe MAJ; Holman SP; Lamport AC; Akay T; Robertson GS
    J Neuroimmunol; 2018 Aug; 321():72-82. PubMed ID: 29957391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
    Hou H; Cao R; Miao J; Sun Y; Liu X; Song X; Guo L
    Int Immunopharmacol; 2016 Jan; 30():171-178. PubMed ID: 26632437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice.
    Martín-Álvarez R; Paúl-Fernández N; Palomo V; Gil C; Martínez A; Mengod G
    J Chem Neuroanat; 2017 Mar; 80():27-36. PubMed ID: 28007551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis.
    Silva RBM; Greggio S; Venturin GT; da Costa JC; Gomez MV; Campos MM
    Mol Neurobiol; 2018 Dec; 55(12):9307-9327. PubMed ID: 29667130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE model of mice.
    Sepasi T; Ghadiri T; Ebrahimi-Kalan A; Bani F; Talebi M; Rahbarghazi R; Khodakarimi S; Beyrampour-Basmenj H; Seidi K; Abbaspour-Ravasjani S; Sadeghi MR; Zarebkohan A; Gao H
    Int J Pharm; 2023 Apr; 636():122815. PubMed ID: 36907279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    Smith PA; Schmid C; Zurbruegg S; Jivkov M; Doelemeyer A; Theil D; Dubost V; Beckmann N
    J Neuroimmunol; 2018 May; 318():103-113. PubMed ID: 29530550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
    Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.
    Camacho-Toledano C; Machín-Díaz I; Calahorra L; Cabañas-Cotillas M; Otaegui D; Castillo-Triviño T; Villar LM; Costa-Frossard L; Comabella M; Midaglia L; García-Domínguez JM; García-Arocha J; Ortega MC; Clemente D
    J Neuroinflammation; 2022 Nov; 19(1):277. PubMed ID: 36403026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
    Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
    J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic neuroprotective effects of Fingolimod and mesenchymal stem cells (MSC) in experimental autoimmune encephalomyelitis.
    Kassis I; Ben-Zwi M; Petrou P; Halimi M; Karussis D
    Immunol Lett; 2021 May; 233():11-19. PubMed ID: 33676976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin and fingolimod modulate Treg/Th17 cells in experimental autoimmune encephalomyelitis by regulating the Akt-mTOR and MAPK/ERK pathways.
    Hou H; Cao R; Quan M; Sun Y; Sun H; Zhang J; Li B; Guo L; Song X
    J Neuroimmunol; 2018 Nov; 324():26-34. PubMed ID: 30205205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
    Rossi S; Lo Giudice T; De Chiara V; Musella A; Studer V; Motta C; Bernardi G; Martino G; Furlan R; Martorana A; Centonze D
    Br J Pharmacol; 2012 Feb; 165(4):861-9. PubMed ID: 21740406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.